Medical Weight Loss in New York City
The STEP and SURMOUNT trials changed what evidence-based medicine considers achievable with weight loss pharmacotherapy. Average reductions of 15-21% of body weight — results that no prior medication class had produced. The mechanism is not appetite suppression through stimulation. It is targeted engagement of the hypothalamic circuits that govern hunger and satiety at the neurological level. Our Manhattan physicians prescribe Semaglutide and Tirzepatide based on your metabolic profile, not a wellness trend.
Clinical Trial Results
What Makes GLP-1 Therapy Different?
Most approaches to weight loss fail not because of insufficient discipline but because of biological resistance. When caloric intake drops, the hypothalamus responds by increasing hunger-driving hormones and reducing metabolic rate — a compensatory mechanism that makes sustained caloric deficit physiologically difficult to maintain. This is not a character flaw. It is the body defending its current weight set point.
GLP-1 receptor agonists interrupt this cycle at the hypothalamic level. By activating GLP-1 receptors in the arcuate nucleus of the brain — the primary hunger-regulation circuit — Semaglutide and Tirzepatide suppress the NPY/AgRP neurons driving hunger and activate the POMC/CART neurons signaling satiety. The hunger reduction patients experience is not willpower enhancement. It is a measurable change in the neurological signal driving appetite.
At TRT New York, GLP-1 therapy is prescribed as part of a physician-supervised weight management program. Your prescribing physician reviews your metabolic panel, hormonal status, cardiovascular profile, and weight history before selecting the appropriate medication, dose, and titration schedule. Monthly monitoring continues throughout.
Why TRT New York for Medical Weight Loss?
- Semaglutide and Tirzepatide — both options available based on your clinical profile
- Comprehensive metabolic and hormonal workup before initiation
- Graduated dose titration to minimize gastrointestinal side effects
- Hormone optimization integrated where clinically indicated — because hormones determine whether weight loss stays lost
Hypothalamic Appetite Control
GLP-1 receptors in the arcuate nucleus of the hypothalamus are activated, suppressing the neuronal populations responsible for hunger drive. Patients describe not reduced motivation to eat — but reduced hunger itself. A fundamentally different biological state.
Insulin Sensitivity Improvement
GLP-1 agonists improve pancreatic beta-cell function and glucose-dependent insulin secretion — addressing the insulin resistance that is both a cause and consequence of obesity in most patients presenting for weight loss.
Cardiovascular Risk Reduction
The SELECT trial demonstrated a 20% reduction in major cardiovascular events with Semaglutide in high-risk patients. GLP-1 agonists have direct anti-inflammatory and vascular effects that extend well beyond weight loss numbers.
Our Medical Weight Loss Programs
Each program page explains the pharmacology, the clinical evidence, who benefits most, and what to expect — so you arrive at your consultation with a clear baseline of knowledge.
How GLP-1 Therapy Works
The pharmacology behind GLP-1 receptor agonists and why they produce durable weight loss.
Semaglutide (Ozempic/Wegovy)
FDA-approved GLP-1 therapy with 14-17% average body weight loss in Phase 3 clinical trials.
Tirzepatide (Mounjaro/Zepbound)
Dual GLP-1/GIP receptor agonist producing 20-22% average body weight loss — highest efficacy in class.
Metabolic Health Program
Integrated GLP-1 therapy with hormone optimization and metabolic monitoring for sustainable results.
Who Is a Candidate for GLP-1 Therapy in New York?
GLP-1 therapy is not appropriate for everyone seeking to lose weight. Clinical candidacy is determined by your metabolic profile, health history, current medications, and the biological context of your weight gain — not by a BMI cutoff alone.
-
BMI ≥30, or ≥27 with comorbidities: Hypertension, pre-diabetes, dyslipidemia, or sleep apnea alongside excess weight represent the FDA-approved indication for Semaglutide (Wegovy) and Tirzepatide (Zepbound).
-
Metabolic resistance to diet and exercise: Patients who have sustained genuine dietary restriction and regular training without adequate weight loss often have hormonal, insulin-related, or hypothalamic mechanisms driving resistance that GLP-1 therapy directly addresses.
-
Desk-bound professionals with visceral weight gain: The abdominal adiposity pattern common in finance and law — driven by cortisol, insulin resistance, and sedentary office hours — responds well to GLP-1 therapy's disproportionate effect on visceral fat.
-
Pre-diabetic patients seeking primary prevention: GLP-1 therapy simultaneously reduces weight and improves pancreatic function, often normalizing pre-diabetic markers alongside primary weight outcomes.
Weight Loss Program at TRT New York
Hormone Optimization + Weight Loss
Low testosterone is both a cause and a consequence of obesity — visceral fat converts testosterone to estrogen via aromatase, worsening the hormonal picture as weight increases. Our physicians assess hormonal status as part of every weight loss workup, because addressing the hormonal driver alongside GLP-1 therapy consistently produces better and more durable results than either intervention alone.
Medical Weight Loss FAQ — New York City
Common questions about Semaglutide and Tirzepatide therapy at TRT New York. Call (332) 237-6820 for personal guidance.
Start Medical Weight Loss in New York City
The pharmacology exists. The clinical evidence is substantial. Whether GLP-1 therapy is appropriate for your situation requires a physician assessment — which is exactly where we start.